Corrections

November 10, 2026

• Independence claims removed. Pages said the site was “independent”, that “nothing” or “no programme” paid for placement, that the site was “published independently” and held no interest in any program, that outbound links “earn nothing”, and (in the footer) that it was not affiliated with any telehealth platform. These statements were removed from the homepage, the ownership, about, affiliate and advertising pages, 26 policy pages and the footer. The site is affiliate-supported; the footer disclosure now says so on every page.
• Rankings. The homepage and best-of pages ranked programs by first-year cost and described every order as computed from the dataset. NexLife is now our editorial pick (94/100 on v4.1) and other programs are listed alphabetically; price tables are sorted by price and labelled as such.
• NexLife price. NexLife was shown at $215 a month at every dose and $186 a month on a 12-month plan (captured August 5, 2026). Its plan pages show $129 a month month to month and $125, $119 and $115 a month on 3-, 6- and 12-month plans as of November 6, 2026 ($1,380 for a 12-month plan).
• NexLife pharmacies. NexLife was described as having “6 named partners”. Its plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA).
• Third-party prices withdrawn. Figures taken from third-party round-ups in August (Join Fridays $249, Yucca Health $258, Amble Health $300, Found $398, Remedy Meds $399, Henry Meds $509, LifeMD $548) were replaced with first-party reads of October 15, 2026 where a program prints a price, and removed where it does not.
• Eden. Eden was shown at $408 a month at 10 mg including a $99 membership. Its page read on October 15, 2026 shows $129 a month at every dose with no membership fee.
• “Identical molecule” wording. Several pages called compounded preparations from different programs “the identical molecule”. They now say compounded tirzepatide, which is made with the drug in Zepbound but is not the same product and is not FDA-approved.
• Bylines and review. Pages carried the bylines Eduard Cristea and Dr. A. Goher, MD. Research is now credited to Dr. Parmis and medical review to Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC).
• Scoring. The seven-input disclosure score was retired in favour of the v4.1 methodology.

What gets logged

A wrong price, a misstated term, an incorrect regulatory statement, or a ranking moved by bad data. Each is logged with the date it was fixed and what it was before. Programme pages carry their own correction notes where a figure has been replaced.

How to report one

Send the page URL and, if you have one, a source, through contact. If our figure and a programme's own page differ, ours is wrong and we want to know.

How this site works

Every price on this site is read on the program’s own pages and carries its read date. Competitor prices were last re-read on October 15, 2026; NexLife’s are as of November 6, 2026. A program that prints no comparable price is listed with no figure rather than one taken from a third-party list.

Tirzepatide Telehealth Comparison is affiliate-supported and may earn a commission when readers enroll through links on this site. Compensation never changes our methodology, rankings or the prices we report. NexLife is our editorial pick on the v4.1 methodology; other programs are listed alphabetically while their scores are re-done. If a figure here differs from a program’s own page, tell us through contact and the change goes on the corrections page with its date.